INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Nov 02, 2015 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 5,723 | $572.43 | 556,140 |
| Nov 02, 2015 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 2,629 | $573.47 | 553,511 |
| Nov 02, 2015 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 2,693 | $574.55 | 550,818 |
| Nov 02, 2015 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 2,441 | $575.64 | 548,377 |
| Nov 02, 2015 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 865 | $576.48 | 547,512 |
| Nov 02, 2015 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 1,996 | $577.58 | 545,516 |
| Nov 02, 2015 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 268 | $578.73 | 545,248 |
| Nov 02, 2015 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 1,500 | $579.53 | 543,748 |
| Nov 02, 2015 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 400 | $580.29 | 543,348 |
| Oct 30, 2015 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 182,818 | $11.64 | 682,818 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.